On another note, while studies are lacking assessing m6A regulated B cell dysregulation in TIME, B cells in the germinal center of a non-tumor model, are tightly controlled by METTL3 and METTL14, indicating their potential application in potential B cell targeted immunotherapy in the future [137, 138]. The gene discussed is METTL3; the disease is neoplasm.